<?xml version="1.0"?>
<template xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="openEHR/v1/Template">
  <id>6d863530-4ff7-4177-8e3f-9ba49cf1b2a3</id>
  <name>Inhaled Medications Croup Pediatric ED UCC Order Group</name>
  <description>
    <lifecycle_state>Initial</lifecycle_state>
    <details>
      <purpose/>
      <use/>
      <misuse/>
    </details>
    <other_details>
      <item>
        <key>MetaDataSet:Sample Set </key>
        <value>Template metadata sample set </value>
      </item>
      <item>
        <key>Acknowledgements</key>
        <value/>
      </item>
      <item>
        <key>Business Process Level</key>
        <value/>
      </item>
      <item>
        <key>Care setting</key>
        <value/>
      </item>
      <item>
        <key>Client group</key>
        <value/>
      </item>
      <item>
        <key>Clinical Record Element</key>
        <value/>
      </item>
      <item>
        <key>Copyright</key>
        <value/>
      </item>
      <item>
        <key>Issues</key>
        <value/>
      </item>
      <item>
        <key>Owner</key>
        <value/>
      </item>
      <item>
        <key>Sign off</key>
        <value/>
      </item>
      <item>
        <key>Speciality</key>
        <value/>
      </item>
      <item>
        <key>User roles</key>
        <value/>
      </item>
    </other_details>
  </description>
  <annotations path="[openEHR-EHR-SECTION.adhoc.v1]">
    <items>
      <item>
        <key>Technical.ï»© Technical Traceability</key>
        <value>{~AHSID~6d863530-4ff7-4177-8e3f-9ba49cf1b2a3~NAME~Inhaled Medications Croup Pediatric ED UCC Order Group}</value>
      </item>
    </items>
  </annotations>
  <annotations path="[openEHR-EHR-SECTION.adhoc.v1]/items[openEHR-EHR-SECTION.clinical_guidance.v1]">
    <items>
      <item>
        <key>CKT.Clinical Guidance</key>
        <value>&lt;p&gt;Systemic administration (PO/IM/IV) of steroids is the preferred treatment for croup. Inhaled budesonide can be considered in severe cases (i.e. impending airway obstruction/requiring repeated doses of epinephrine) OR in children who cannot receive or tolerate systemic steroids.&lt;br&gt;&amp;nbsp;&lt;br&gt;Children with croup should not require nebulized epinephrine to treat stridor unless stridor is occurring at rest AND accompanied by perceived distress or discomfort or increased work of breathing.&amp;nbsp;&lt;/p&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;p&gt;&lt;u&gt;&lt;strong&gt;Nebulized EPINEPHrine&lt;/strong&gt;&lt;/u&gt;&lt;br&gt;Nebulization should be used in children with impending respiratory failure as evidenced by low room air saturation and/or abnormal mental status.&amp;nbsp;&lt;br&gt;&amp;nbsp;&lt;br&gt;May be repeated back to back in children with severe distress/ near respiratory failure but requires frequent re-evaluation.&amp;nbsp;&lt;br&gt;&lt;strong&gt;Contraindications:&lt;/strong&gt; Caution should be exercised when used in children with narrow angle glaucoma or cardiac abnormalities (consider cardiorespiratory monitor during administration).&amp;nbsp;&lt;br&gt;&amp;nbsp;&lt;br&gt;&lt;u&gt;&lt;strong&gt;EPINEPHrine via a Metered Dose Inhaler (MDI)&lt;/strong&gt;&lt;/u&gt;&lt;br&gt;If treatment setting requires avoidance of nebulization as a AGMP, epinephrine administered via an MDI with a mask spacer is a treatment option and, based on Canadian-wide pediatric ED quality assurance project, is safe and effective in most, but not all children with severe respiratory distress. If clinicians opt to use epinephrine MDI, children should be evaluated within 10 minutes following treatment. If clinical response is not adequate, repeat treatment with an additional five puffs. If response within another 10 minutes is inadequate, switching to nebulized epinephrine is recommended.&lt;br&gt;&amp;nbsp;&lt;br&gt;&lt;strong&gt;&lt;u&gt;Budesonide&lt;/u&gt;&lt;/strong&gt;&lt;br&gt;Consider in a child with severe croup, or child with persistent vomiting.&amp;nbsp;&lt;br&gt;&amp;nbsp;&lt;br&gt;Inhaled budesonide is a consideration in severe cases (i.e. repeated doses of epinephrine and ongoing stridor) and/or no ability/access to provide systemic steroid.&lt;br&gt;More commonly causes agitation than oral administration and more expensive than dexamethasone. Budesonide may be mixed with epinephrine and administered simultaneously.&amp;nbsp;&lt;br&gt;&amp;nbsp;&lt;/p&gt;</value>
      </item>
    </items>
  </annotations>
  <annotations path="[openEHR-EHR-SECTION.adhoc.v1]/items[openEHR-EHR-SECTION.adhoc.v1 and name/value=&apos;Nebulized EPINEPHrine&apos;]/items[openEHR-EHR-INSTRUCTION.section_supporting_context.v1]">
    <items>
      <item>
        <key>Transform.Preselected</key>
        <value>&lt;p&gt;N&lt;/p&gt;</value>
      </item>
    </items>
  </annotations>
  <annotations path="[openEHR-EHR-SECTION.adhoc.v1]/items[openEHR-EHR-SECTION.adhoc.v1 and name/value=&apos;Nebulized EPINEPHrine&apos;]/items[openEHR-EHR-INSTRUCTION.service_request.v1]/activities[at0001]">
    <items>
      <item>
        <key>CKT.Content Details</key>
        <value>&lt;p&gt;Admin Instructions: Via nebulizer&lt;/p&gt;</value>
      </item>
      <item>
        <key>Catalogue Pattern.Configuration Notes</key>
        <value>&lt;p&gt;This order auto selects when panel &quot;Nebulized EPINEPHrine&quot; is selected&lt;/p&gt;</value>
      </item>
    </items>
  </annotations>
  <annotations path="[openEHR-EHR-SECTION.adhoc.v1]/items[openEHR-EHR-SECTION.adhoc.v1 and name/value=&apos;Nebulized EPINEPHrine&apos;]/items[openEHR-EHR-INSTRUCTION.service_request.v1]/activities[at0156]">
    <items>
      <item>
        <key>Transform.Preselected</key>
        <value>&lt;p&gt;Y&lt;/p&gt;</value>
      </item>
    </items>
  </annotations>
  <annotations path="[openEHR-EHR-SECTION.adhoc.v1]/items[openEHR-EHR-SECTION.adhoc.v1 and name/value=&apos;EPINEPHrine via a Metered Dose Inhaler (MDI)&apos;]/items[openEHR-EHR-INSTRUCTION.section_supporting_context.v1]">
    <items>
      <item>
        <key>Transform.Preselected</key>
        <value>&lt;p&gt;N&lt;/p&gt;</value>
      </item>
    </items>
  </annotations>
  <annotations path="[openEHR-EHR-SECTION.adhoc.v1]/items[openEHR-EHR-SECTION.adhoc.v1 and name/value=&apos;EPINEPHrine via a Metered Dose Inhaler (MDI)&apos;]/items[openEHR-EHR-INSTRUCTION.service_request.v1 and name/value=&apos;EPINEPHrine inhaler 0.125 mg; 5 puffs, inhalation, once&apos;]/activities[at0001]">
    <items>
      <item>
        <key>CKT.Content Details</key>
        <value>&lt;p&gt;Admin Instructions:&amp;nbsp;Inhaled via metered dose inhaler (MDI) without a spacer.&lt;br&gt;Approved during COVID-19 pandemic as an alternative to nebulized epinephrine in the management of croup in pediatrics.&lt;/p&gt;</value>
      </item>
    </items>
  </annotations>
  <annotations path="[openEHR-EHR-SECTION.adhoc.v1]/items[openEHR-EHR-SECTION.adhoc.v1 and name/value=&apos;EPINEPHrine via a Metered Dose Inhaler (MDI)&apos;]/items[openEHR-EHR-INSTRUCTION.service_request.v1 and name/value=&apos;EPINEPHrine inhaler 0.125 mg; 5 puffs, inhalation, every 10 minutes, as needed, for respiratory distress inadequately resolved and absent signs of toxicity (tachycardia, jittery)&apos;]/activities[at0001]">
    <items>
      <item>
        <key>CKT.Content Details</key>
        <value>&lt;p&gt;Admin Instructions:&amp;nbsp;Inhaled via metered dose inhaler (MDI) without a spacer.&lt;br&gt;Approved during COVID-19 pandemic as an alternative to nebulized epinephrine in the management of croup in pediatrics.&lt;/p&gt;</value>
      </item>
    </items>
  </annotations>
  <annotations path="[openEHR-EHR-SECTION.adhoc.v1]/items[openEHR-EHR-SECTION.adhoc.v1 and name/value=&apos;Budesonide: Consider in child with severe croup, or child with persistent vomiting&apos;]/items[openEHR-EHR-INSTRUCTION.section_supporting_context.v1]">
    <items>
      <item>
        <key>Transform.Preselected</key>
        <value>&lt;p&gt;N&lt;/p&gt;</value>
      </item>
    </items>
  </annotations>
  <annotations path="[openEHR-EHR-SECTION.adhoc.v1]/items[openEHR-EHR-SECTION.adhoc.v1 and name/value=&apos;Budesonide: Consider in child with severe croup, or child with persistent vomiting&apos;]/items[openEHR-EHR-INSTRUCTION.service_request.v1]/activities[at0001]">
    <items>
      <item>
        <key>Catalogue Pattern.Configuration Notes</key>
        <value>&lt;p&gt;This order is auto selected when panel &quot;Budesonide: Consider in child with severe croup, or child with persistent vomiting&quot; is selected&lt;/p&gt;</value>
      </item>
      <item>
        <key>CKT.Content Details</key>
        <value>&lt;p&gt;Admin Instructions:&amp;nbsp;Budesonide may be mixed with epinephrine and administered simultaneously&lt;/p&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;p&gt;Other order questions:&lt;/p&gt;&lt;p&gt;This is a restricted drug. What is the indication for this order?:&lt;/p&gt;&lt;p&gt;Patients who cannot be treated ith MDI with spacer&lt;/p&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;p&gt;Specify the reason why patient cannot be treated with MDI with spacer:&amp;nbsp;&lt;/p&gt;&lt;p&gt;To be given with nebulized epinephrine, no evidence for fluticasone MDI&lt;/p&gt;</value>
      </item>
    </items>
  </annotations>
  <annotations path="[openEHR-EHR-SECTION.adhoc.v1]/items[openEHR-EHR-SECTION.adhoc.v1 and name/value=&apos;Budesonide: Consider in child with severe croup, or child with persistent vomiting&apos;]/items[openEHR-EHR-INSTRUCTION.service_request.v1]/activities[at0156]">
    <items>
      <item>
        <key>Transform.Preselected</key>
        <value>&lt;p&gt;Y&lt;/p&gt;</value>
      </item>
    </items>
  </annotations>
  <definition xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.adhoc.v1" concept_name="Ad hoc heading" max="1" name="Inhaled Medications">
    <Item xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.clinical_guidance.v1" concept_name="Clinical Guidance" path="/items"/>
    <Item xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.adhoc.v1" concept_name="Ad hoc heading" max="1" path="/items" name="Nebulized EPINEPHrine">
      <Item xsi:type="INSTRUCTION" archetype_id="openEHR-EHR-INSTRUCTION.section_supporting_context.v1" concept_name="Section supporting context" path="/items"/>
      <Item xsi:type="INSTRUCTION" archetype_id="openEHR-EHR-INSTRUCTION.service_request.v1" template_id="48cfca84-31a2-40e5-ab72-2e13238f525a" concept_name="PHARM EPINEPHrine injection for inhalation use 1 mg/mL Order" max="1" path="/items" name="EPINEPHrine injection for inhalation use 1 mg/mL; 5mg inhalation, once"/>
    </Item>
    <Item xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.adhoc.v1" concept_name="Ad hoc heading" max="1" path="/items" name="EPINEPHrine via a Metered Dose Inhaler (MDI)">
      <Item xsi:type="INSTRUCTION" archetype_id="openEHR-EHR-INSTRUCTION.section_supporting_context.v1" concept_name="Section supporting context" path="/items"/>
      <Item xsi:type="INSTRUCTION" archetype_id="openEHR-EHR-INSTRUCTION.service_request.v1" template_id="d84eab5a-7d5f-4700-9f51-70afef3fd6d1" concept_name="PHARM EPINEPHrine Inhaler 0.125 mg/actuation Order" max="1" path="/items" name="EPINEPHrine inhaler 0.125 mg; 5 puffs, inhalation, once"/>
      <Item xsi:type="INSTRUCTION" archetype_id="openEHR-EHR-INSTRUCTION.service_request.v1" template_id="d84eab5a-7d5f-4700-9f51-70afef3fd6d1" concept_name="PHARM EPINEPHrine Inhaler 0.125 mg/actuation Order" max="1" path="/items" name="EPINEPHrine inhaler 0.125 mg; 5 puffs, inhalation, every 10 minutes, as needed, for respiratory distress inadequately resolved and absent signs of toxicity (tachycardia, jittery)"/>
    </Item>
    <Item xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.adhoc.v1" concept_name="Ad hoc heading" max="1" path="/items" name="Budesonide: Consider in child with severe croup, or child with persistent vomiting">
      <Item xsi:type="INSTRUCTION" archetype_id="openEHR-EHR-INSTRUCTION.section_supporting_context.v1" concept_name="Section supporting context" path="/items"/>
      <Item xsi:type="INSTRUCTION" archetype_id="openEHR-EHR-INSTRUCTION.service_request.v1" template_id="13ea8e21-4d93-4e03-9488-26e4eaf57433" concept_name="PHARM budesonide Nebule 0.5 mg/mL Order" max="1" path="/items" name="budesonide nebule 0.5 mg/mL; 2mg, inhalation, daily"/>
    </Item>
  </definition>
  <integrity_checks xsi:type="ArchetypeIntegrity" archetype_id="openEHR-EHR-SECTION.adhoc.v1">
    <digest id="MD5-CAM-1.0.1">8AE70853975A75254E6D39A8DE3652AF</digest>
  </integrity_checks>
  <integrity_checks xsi:type="ArchetypeIntegrity" archetype_id="openEHR-EHR-SECTION.clinical_guidance.v1">
    <digest id="MD5-CAM-1.0.1">4B2F0F6CD593E442DA9C30277A3EA9CF</digest>
  </integrity_checks>
  <integrity_checks xsi:type="ArchetypeIntegrity" archetype_id="openEHR-EHR-INSTRUCTION.section_supporting_context.v1">
    <digest id="MD5-CAM-1.0.1">A7EC4E4C870D8C3431B29F6514353416</digest>
  </integrity_checks>
  <integrity_checks xsi:type="ArchetypeIntegrity" archetype_id="openEHR-EHR-INSTRUCTION.service_request.v1">
    <digest id="MD5-CAM-1.0.1">AD8DFB192E67715F0D9E11E95E674AD0</digest>
  </integrity_checks>
  <integrity_checks xsi:type="ArchetypeIntegrity" archetype_id="openEHR-EHR-CLUSTER.service_request_information.v1">
    <digest id="MD5-CAM-1.0.1">230A8D964017E1FD7AC82EBDEE0202A6</digest>
  </integrity_checks>
</template>